Ken Griffin Fulcrum Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$3.18 - $9.74 $252,174 - $772,382	79,300 Added 68.54%	195,000 $696,000
Q2 2024 Aug 14, 2024	BUY	$5.98 - $9.31 $376,142 - $585,599	62,900 Added 119.13%	115,700 $717,000
Q1 2024 May 15, 2024	SELL	$6.7 - $12.0 $1.87 Million - $3.35 Million	-279,300 Reduced 84.1%	52,800 $498,000
Q4 2023 Feb 14, 2024	SELL	$3.18 - $6.86 $57,240 - $123,480	-18,000 Reduced 5.14%	332,100 $2.24 Million
Q3 2023 Nov 14, 2023	BUY	$3.25 - $6.08 $32,825 - $61,408	10,100 Added 2.97%	350,100 $1.55 Million
Q2 2023 Aug 14, 2023	SELL	$2.26 - $3.8 $17,628 - $29,640	-7,800 Reduced 2.24%	340,000 $1.12 Million
Q1 2023 May 15, 2023	BUY	$2.83 - $13.99 $71,882 - $355,346	25,400 Added 7.88%	347,800 $991,000
Q4 2022 Feb 14, 2023	SELL	$5.01 - $8.35 $33,066 - $55,110	-6,600 Reduced 2.01%	322,400 $2.35 Million
Q3 2022 Nov 14, 2022	SELL	$4.92 - $9.1 $725,700 - $1.34 Million	-147,500 Reduced 30.95%	329,000 $2.66 Million

150

52.2M

6.91M

1.9M

Ticker FULC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,038,900
Market Cap $230M
Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.